Empowering Public Health, Drawing a New Blueprint for the IVD Industry

As an essential cornerstone of the modern healthcare system, in vitro diagnostics (IVD) serves as critical support for disease screening, precision diagnosis and treatment, and therapeutic efficacy monitoring. It runs through the entire workflow of medical services and plays a vital role in safeguarding public health.

Looking back over four decades of development, China’s in vitro diagnostics industry has forged ahead with consistent dedication. It has achieved transformative leaps: growing from scratch, expanding in scale, and evolving from weakness to strength. The industrial framework has kept improving, innovation capacity has risen steadily, and the market size has continued to expand. IVD has become one of the most dynamic and promising segments within China’s medical device sector.

Authoritative industry forecasts project steady growth for China’s IVD sector over the next five years, with a compound annual growth rate (CAGR) of 5%–8%. The domestic IVD market is expected to exceed 190 billion yuan by 2029 (Source: China In Vitro Diagnostics Industry Development Blue Book (2023–2024)). These figures fully demonstrate the strong market resilience, broad prospects and sustained endogenous growth momentum of China’s IVD industry. They also signal that the sector has entered a new phase of innovation-driven upgrading and refined development, which raises higher requirements for technological innovation, industrial collaboration and standardized operation.

As an authoritative industry reference work for the IVD field, the China In Vitro Diagnostics Industry Development Blue Book presents a comprehensive overview of the industry landscape in 2023–2024. Featuring professional insights, detailed statistics and rigorous analysis, it systematically summarizes technological innovations, market conditions, industrial chain structure and latest developments of the domestic IVD industry in these two years, while accurately identifying future trends, opportunities and challenges.

On this occasion, Shen Ling, Marketing Director of Beijing Hamamatsu Photonics Technology Co., Ltd. (BHP), was invited to participate in the compilation of the China In Vitro Diagnostics Industry Development Blue Book (2023–2024) and received a special certificate of appreciation from the editorial committee.

This honor represents high recognition from authoritative industry institutions and peers of BHP’s R&D strength, manufacturing capability and contributions to the sector.

With years of deep engagement in photonics technology, BHP has consistently focused on R&D and innovation of upstream core technologies and key components for IVD. Leveraging its core strengths in photonics, the company keeps advancing key segments along the IVD industrial chain, breaking technical barriers and optimizing its product portfolio. It provides robust core technologies and hardware support for the localization, precision and high-end development of IVD instruments, and enables a full spectrum of downstream testing and diagnostic applications.

Facing the promising outlook of the industry, BHP will continue to pursue innovation-driven development and consolidate its core competitiveness:

• Advance cutting-edge photonics research, iterate high-end optoelectronic core components, and break down technological barriers previously held by imported products;

• Collaborate with upstream and downstream partners in the industrial chain to build joint innovation platforms and connect the full value chain spanning components, finished instruments and clinical applications;

• Take an active part in industry development initiatives, share practical experience, and support the standardized, high-quality growth of the sector.

Going forward, BHP will join hands with partners across the industry to pool strengths and explore innovative pathways. Together, they will promote continuous quality improvement and breakthroughs for China’s IVD industry, and jointly write a new chapter for the high-quality development of China’s IVD sector.